Technology

Stem cell renewal and maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans.

Our first clinical approach will be the demonstration of improved outcomes after spinal fusion surgeries. Our product has expansion opportunities to other bone reconstructive procedures including osseointegration of dental and orthopedic implants (knee and hip replacements), fracture repair, total joint arthroplasty revisions, and others.

 

 

ART352-L:

Regenerative Medicine for Better Bone Formation

Large Growing 

Market(s)

Novel Product with

Compelling Data

Robust Pipeline

Potential

De-Risked Phase 2

Opportunity

Proven Executive

Leadership

Spinal fusion:

$5B+ US/$3B ex-US market

Total joint arthroplasty (hip/knee):

$9.5B US market

Disruptive, clinical stage biologic for safe bone healing enchancement

  • Liposomally delivered rhWnt3 protein activates resident stem cells to osteogenic phenotype.
  • Potential for superior bone formation vs. autograft
Spinal fusion for degenerative lumbar spine disorders as initial indication (IND Q1 ’20)

  • Goal is more rapid fusion, higher fusion rates and durability

Scientifically proven platform for pipeline expansion to arthroplasty, fracture and dental applications

 

GMP manufacturing complete

ART352-L:

Regenerative Medicine for Better BoneFormation

Large Growing 

Market(s)

Novel Product with

Compelling Data

Robust Pipeline

Potential

De-Risked Phase 2

Opportunity

Proven Executive

Leadership

Spinal fusion:

$5B+ US/$3B ex-US market

Spinal fusion for degenerative lumbar spine disorders as initial indication (IND Q1 ’20)

  • Goal is more rapid fusion, higher fusion rates and durability

Total join arthroplasty (hip/knee):

$9.5B US market

Scientifically proven platform for pipeline expansion to arthroplasty, fracture, and dental applications

 

Disruptive, clinical stage biologic for sale bone healing enchancement

  • Liposomally delivered rhWnt3 protein activates resident stem cells to osteogenic phenotype.
  • Potential for superior bone formation vs autograft

GMP manufacturing complete

Unmet medical need:

Autograft efficacy declines with age.

In patients >50, autograft becomes unreliable. This functional decline can be attributed to aging skeletal stem cells & insufficient growth factors.

ART352-L

addresses this deficit

Ankasa’s proprietary Wnt3 protein therapeutic activates skeletal stem cells and accelerates bone regeneration in animal models of spinal fusion, segmental defects and osseointegration.

Pipeline

Leveraging established GMP manufacturing, critical scientific know-how and clinical development expertise

Multiple value inflection points through continued advancement to additional indications

+ Internal Expansion

  • Lumbar spine

+ Spine Expansion

  • Cervical
+ Indication Expansion

  • Total Joint Arthoplasty
  • Dental
+ Tissue Type Expansion

  • cartilage and tendon repair

Pipeline

Leveraging established GMP manufacturing, critical scientific know-how and clinical development expertise

Multiple value inflection points through continued advancement to additional indications

+ Internal Expansion

Lumbar spine

+ Spine Expansion

Cervical

+ Indication Expansion

Total Joint Arthoplasty

Dental

+ Tissue Type Expansion

Carttiledge and tendon repair?

Pipeline

Leveraging established GMP manufacturing, critical scientific know- how and clinical development expertise

Multiple value inflection points through continued advancement to additional indications

+ Internal Expansion

Lumbar spine

+ Spine Expansion

Cervical

+ Indication Expansion

Total Join Arthoplasty

Dental

+ Tissue Type Expansion

Carttiledge and tendor repair?

© 2019 Ankasa. All Rights Reserved